查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014538

纖維蛋白膠市場：全球市場按產品類型、配方類型、技術、應用和最終用戶分類的預測——2026-2032年

Fibrin Sealant Market by Product Type, Formulation Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，纖維蛋白膠市場價值將達到 5.1003 億美元，到 2026 年將成長至 5.8459 億美元，到 2032 年將達到 13.1632 億美元，年複合成長率為 14.50%。

主要市場統計數據
基準年 2025 510,030,000 美元
預計年份：2026年 5.8459億美元
預測年份 2032 1,316,320,000 美元
複合年成長率 (%) 14.50%

對纖維蛋白膠進行簡明策略概述：從臨床進展、監管趨勢和影響應用趨勢的商業性因素等方面說明。

本執行摘要概述了纖維蛋白膠的發展趨勢，並將該技術定位於外科創新與複雜供應鏈的交匯點。近年來，藥物化學、給藥技術和臨床證據的進步，使纖維蛋白膠從輔助產品躍升為影響手術效率、止血效果和手術全期工作流程的策略工具。因此，臨床、商業和採購部門的相關人員正在重新評估產品選擇、手術室規程和採購實踐，使其既符合臨床目標，又符合組織限制。

纖維蛋白膠領域正在發生新的變革，這是由給藥方法、臨床結果、報銷趨勢和引入模式的創新所驅動的。

纖維蛋白膠的市場格局正經歷著變革性的轉變，這主要歸因於技術、臨床實踐和商業化等多方面因素的共同作用。給藥方式的創新拓展了密封劑的實際應用範圍，而配方的不斷改進則提高了操作便利性，並增強了其與各種外科手術流程的兼容性。這些技術進步的動力在於不斷成長的臨床數據，這些數據更清晰地展現了每種手術的益處，從而促使臨床醫生對符合其偏好的專用產品形式的需求日益成長。

評估 2025 年美國關稅對纖維蛋白膠採購、供應鏈韌性、籌資策略和臨床實踐准入的累積影響。

美國計劃於2025年實施的關稅措施將使纖維蛋白膠的供應鏈和醫院採購慣例更加複雜。關稅調整將直接影響成品和關鍵原料的到貨成本，進而可能影響製造商和分銷合作夥伴的採購決策。在許多情況下，供應商可能會重新評估其總服務成本並最佳化製造地，修改原料供應契約，或調整定價策略，以在確保利潤率的同時維持服務水準。

有助於制定策略的細分洞察，提取產品類型、應用子細分、最終用戶環境、配方選擇和技術差異。

細分市場提供了必要的分析框架，可以將產品屬性轉化為臨床和商業性選擇。基於產品類型的液體配方、貼片式基質和噴霧給藥系統之間的差異，決定了密封劑如何融入外科手術、儲存和處理流程以及臨床醫生的偏好。液體配方通常便於在狹小空間內進行精確塗抹；貼片可在止血或組織密封需要大面積接觸時提供結構覆蓋；而噴霧系統則可快速均勻地應用於較大面積。

區域洞察，探索美洲、歐洲、中東和非洲以及亞太地區的需求促進因素、報銷框架、監管細微差別以及臨床實踐的差異。

區域趨勢對監管路徑、支付方互動以及臨床醫生的診療模式均有顯著影響，因此，從區域觀點出發制定有效策略至關重要。在美洲，醫療保健採購者往往優先考慮臨床證據和總體擁有成本 (TCO) 的結合，而供應商則經常進行價值論證計畫和上市後監測，以支援產品推廣應用。該地區的採購週期涉及與醫院集團的複雜談判，並可能受到國家報銷框架和醫療服務提供者處方集的影響，因此，制定符合區域實際情況的商業性策略至關重要。

公司對纖維蛋白膠的產品系列、創新軌跡、商業化策略、競爭定位和市場推出的洞察。

企業層面的行動反映了其在創新投資方向、商業模式建構以及夥伴關係關係選擇方面的策略考量。注重產品組合廣度的企業通常會提供多種產品形式，例如液體、貼片和噴霧劑，並將每種產品與明確的臨床應用案例相結合，以促進臨床醫生的採納。另一方面，專注於平台深度的企業則會不斷改進核心技術，以拓展適應症並提升營運體驗。這種做法或許能夠贏得臨床醫師的強力支持，但在需要多種治療方式的環境中，其吸引力可能有限。

為行業領導者提供實用建議，以最佳化產品開發、增強供應韌性、提高支付方參與度並加快臨床醫生採用。

產業領導者應採取切實可行的策略步驟，以平衡短期業務永續營運與中期臨床和商業性定位。首先，透過採購多元化、提高物流透明度以及協商確保價格穩定和在供應中斷期間優先分配的合約條款，增強供應鏈韌性。其次，使產品開發藍圖與明確的臨床挑戰保持一致，並優先改善那些能夠縮短給藥時間、降低製備複雜性以及提高與常見手術流程相容性的方面。

調查方法，包括資料收集方法、一手和二手資訊的整合、檢驗方案和分析方法。

本研究整合了多種調查方法，以確保其可靠性和有效性。主要調查方法包括對執業外科醫生、手術室護理主管、採購負責人和供應鏈經理進行結構化訪談，以收集關於產品處理、臨床權衡和採購限制的第一手觀點。這些定性資訊與同行評審的臨床文獻和指南的系統性回顧進行交叉比對，以檢驗臨床結論並識別特定手術的證據缺口。

簡潔的結論整合了策略意義和可操作的後續步驟，旨在為尋求臨床影響和商業性價值的相關人員提供協助。

本分析整合了臨床、商業、監管和供應鏈觀點，旨在為相關人員提供一致的洞察。證據表明，臨床應用越來越傾向於選擇能夠提高治療效率和提供可驗證療效的產品，而採購決策則同時受到成本和供應商可靠性的雙重影響。不斷發展的給藥技術和支付方的嚴格審查，都要求制定一項整合產品創新、提供可靠證據並為臨床醫生提供切實支持的綜合策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：纖維蛋白膠市場：依產品類型分類

  • 液體
  • 修補
  • 噴

第9章：依配方類型分類的纖維蛋白膠市場

  • 預混合料
  • 兩件套

第10章：纖維蛋白膠市場：依技術分類

  • 手動應用
  • 噴灑應用

第11章：纖維蛋白膠市場：依應用領域分類

  • 心血管系統
    • 旁路
    • 閥門維修
  • 牙科
  • 一般外科
    • 腹部
    • 胸部
  • 神經外科
  • 整形外科
    • 關節重組
    • 創傷固定
  • 創傷護理

第12章：纖維蛋白膠市場：依最終用戶分類

  • 門診手術中心
  • 診所
  • 醫院

第13章：纖維蛋白膠市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：纖維蛋白膠市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：纖維蛋白膠市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國纖維蛋白膠市場

第17章：中國纖維蛋白膠市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Bayer AG
  • CryoLife, Inc.
  • CSL Behring GmbH
  • Ethicon Inc.
  • FzioMed Inc.
  • Haemacure Corporation
  • Hemarus Therapeutics（India）Pvt. Ltd.
  • Hemostasis LLC
  • Hualan Biological Engineering Inc.
  • Hunan Kelun-Biotech Co., Ltd.
  • Integra LifeSciences Corporation
  • LFB Group
  • Mallinckrodt Pharmaceuticals Holdings Inc.
  • Omrix Biopharmaceuticals Ltd.
  • Omrix Biopharmaceuticals, Inc.
  • Sanofi SA
  • Shanghai Haoyuan Biological Manufacturing Co., Ltd.
  • Shanghai Haoyuan Biological Manufacturing Co., Ltd.
  • Shanghai Hualan Biological Engineering Inc.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Tissuemed Ltd.
Product Code: MRR-4348D129FB3E

The Fibrin Sealant Market was valued at USD 510.03 million in 2025 and is projected to grow to USD 584.59 million in 2026, with a CAGR of 14.50%, reaching USD 1,316.32 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 510.03 million
Estimated Year [2026] USD 584.59 million
Forecast Year [2032] USD 1,316.32 million
CAGR (%) 14.50%

A concise strategic overview of fibrin sealant that contextualizes clinical advances, regulatory dynamics, and commercial levers shaping adoption trends

This executive summary introduces the evolving landscape of fibrin sealants, situating the technology at the intersection of surgical innovation and supply chain sophistication. Over recent years, advancements in formulation chemistry, delivery techniques, and clinical evidence have elevated sealants from adjunctive products to strategic tools that influence procedural efficiency, hemostasis outcomes, and perioperative workflows. As a result, stakeholders across clinical, commercial, and procurement functions are reassessing product selection, operating room protocols, and purchasing practices to align with both clinical objectives and institutional constraints.

The introduction clarifies the fundamental attributes and clinical rationale that underpin fibrin sealant adoption, emphasizing the ways in which product form and delivery method interact with surgical indications and facility capacities. It also frames the broader regulatory and reimbursement backdrop that influences procurement decisions and clinician preferences, including growing emphasis on real-world evidence and value-based care metrics. By grounding readers in these primary themes, the section prepares decision-makers to evaluate tactical choices in product adoption, clinical training, and supplier engagement.

Finally, the introduction outlines the structure of the full analysis and highlights how the subsequent sections interrelate: technology and product innovations inform segmentation and clinical use cases, which in turn interact with regional regulatory environments and recent trade policy developments to shape procurement strategies. This framing ensures readers can move from high-level context to operationally relevant conclusions without losing sight of cross-functional implications

Emerging transformative shifts in the fibrin sealant landscape driven by delivery innovation, clinical outcomes, reimbursement dynamics, and adoption patterns

The landscape for fibrin sealants is experiencing transformative shifts driven by converging forces in technology, clinical practice, and commercialization. Innovations in delivery approaches have expanded the practical settings in which sealants are used, while iterative formulation improvements have increased handling convenience and broadened compatibility with diverse surgical workflows. These technical evolutions are being reinforced by a proliferation of clinical data that more clearly delineates procedure-specific benefits, which in turn is driving demand for specialized product formats aligned to clinician preferences.

Concurrently, payer dynamics and hospital procurement strategies are reshaping commercial realities. Increasing scrutiny on procedural costs, bundled payment models, and outcome-based purchasing means that product differentiation must be substantiated by demonstrable value in efficiency, complication reduction, or length-of-stay improvements. As stakeholders respond, new partnership models and distribution strategies are emerging that emphasize integrated solutions-training, procedural protocols, and post-market evidence collection-rather than singular product transactions.

Moreover, the role of surgeon and OR leadership preferences cannot be overstated; clinician champions often accelerate local adoption when supported by clear clinical data and seamless intraoperative workflows. Taken together, these shifts signal a market that rewards companies and health systems able to synchronize product innovation with evidence generation, reimbursement alignment, and targeted commercialization, thereby moving the field from commodity purchasing toward strategic, evidence-driven procurement

Assessing the cumulative impact of United States tariffs for 2025 on fibrin sealant procurement, supply chain resilience, sourcing strategies, and clinical access

The United States tariff actions scheduled for 2025 introduce a new layer of complexity for fibrin sealant supply chains and hospital procurement practices. Tariff adjustments can directly influence landed costs for finished products and critical inputs, thereby affecting sourcing decisions made by manufacturers and distribution partners. In many cases, suppliers will evaluate the total cost-to-serve and may reoptimize their manufacturing footprints, alter supplier contracts for raw materials, or adjust pricing strategies to preserve margins while maintaining service levels.

For clinical users and procurement teams, the immediate impacts are likely to manifest through changed contract negotiations, potential re-evaluation of supplier multi-sourcing strategies, and a heightened emphasis on inventory planning and contingency buffers. Hospitals and ambulatory centers may respond by prioritizing agreement terms that offer predictable pricing and guaranteed supply, or by exploring alternative products and local sourcing arrangements where feasible. In parallel, manufacturers with diversified production sites or vertically integrated supply chains may be comparatively better positioned to absorb tariff-related cost increases without passing the entire burden to purchasers.

Clinically, any disruptions in product availability could influence procedural scheduling and device selection, particularly in specialty areas where product substitution is operationally burdensome. Therefore, risk mitigation measures such as dual-sourcing, expanded safety stock policies, and enhanced logistics visibility are likely to be central to institutional responses. Overall, the tariff environment underscores the need for both suppliers and buyers to develop adaptive supply chain strategies that reconcile regulatory shifts with the imperative to maintain clinical continuity and cost predictability

Segmentation insights distilling product types, application subsegments, end user settings, formulation options, and technology differences to inform strategy

Segmentation offers the analytical scaffolding required to translate product attributes into clinical and commercial choices. Based on Product Type, differentiation among liquid formulations, patch-based matrices, and spray delivery systems determines how a sealant integrates into operative technique, storage and handling protocols, and clinician preference. Liquid formats typically facilitate precise placement in confined spaces, patch configurations can deliver structural coverage where hemostasis and tissue sealing need broader contact, and spray systems enable rapid, uniform application across larger surfaces.

Based on Application, clinical value is shaped by procedure-specific requirements that range from cardiovascular interventions such as bypass and valve repair to dental and neurosurgical contexts, as well as common general surgery practices including abdominal and thoracic procedures. Orthopedic uses span joint reconstruction and trauma fixation where mechanical stability and hemostasis intersect, while wound care applications emphasize adhesion and healing characteristics in mixed outpatient and inpatient settings. These application distinctions inform training needs, choice of formulation, and intraoperative logistics.

Based on End User, the operational realities of ambulatory surgical centers, outpatient clinics, and hospitals influence product selection, procurement cadence, and inventory management. Formulation Type further stratifies market dynamics: pre mixed preparations offer convenience and reduced setup time, whereas two component kits provide longer shelf stability and flexibility in dosing. Finally, Based on Technology, manual application versus spray application presents trade-offs between precision and speed, and the decision to adopt a particular technology is frequently driven by the interplay of clinical indication, OR throughput goals, and the learning curve for surgical teams. Integrating these segmentation lenses enables stakeholders to align product development, portfolio management, and commercialization strategies with nuanced clinical use cases and facility capabilities

Regional insights exploring demand drivers, reimbursement frameworks, regulatory nuances, and clinical practice variations across Americas, EMEA, and Asia-Pacific

Regional dynamics materially influence regulatory pathways, payer interactions, and clinician practice patterns, so a geography-sensitive view is essential for effective strategy. In the Americas, healthcare purchasers tend to prioritize a combination of clinical evidence and total cost of ownership, and suppliers frequently engage in value demonstration programs and post-market studies to support adoption. Procurement cycles in this region involve complex hospital group negotiations and can be affected by national reimbursement frameworks and institutional formularies, necessitating tailored commercial approaches.

Europe, Middle East & Africa presents a heterogeneous regulatory and reimbursement landscape where national health technology assessment processes and local hospital procurement policies shape adoption. In several EMEA markets, demonstrating cost-effectiveness through health economic modeling and real-world outcomes is a decisive factor in gaining traction, while markets with constrained resources may favor multi-use or cost-efficient options that align with local supply capabilities. Local regulatory nuance and import considerations can also dictate how suppliers structure distribution and support services.

Asia-Pacific displays rapid clinical adoption in certain urban centers alongside emerging demand in broader regional markets; here, supplier success often depends on navigating diverse regulatory approvals, establishing robust local distribution networks, and supporting clinician education at scale. Across all regions, the ability to adapt training, evidence generation, and supply chain strategies to regional priorities is a key differentiator for organizations seeking sustainable commercial success and clinical impact

Company insights on product portfolios, innovation trajectories, commercialization tactics, competitive positioning, and go-to-market in fibrin sealant

Company-level behavior reflects strategic choices about where to invest in innovation, how to structure commercial models, and which partnerships to pursue. Organizations that emphasize portfolio breadth tend to offer multiple product formats-liquids, patches, sprays-and position each against clear clinical use cases to simplify adoption for clinicians. Others focus on platform depth, iterating on a core technology to expand indications or improve handling, which can create strong clinician loyalty but may limit appeal in settings that demand multiple modalities.

Innovation pipelines are increasingly judged not just on formulation novelty but on how new products reduce procedural complexity, shorten OR time, or lower complication rates. Commercially, firms are experimenting with bundled offerings that combine product supply with surgeon training, intraoperative decision support, and post-market evidence programs aimed at demonstrating downstream economic value. Competitive positioning often hinges on the ability to demonstrate these integrated benefits rather than on single-feature claims.

Partnership strategies, including collaborations with distribution partners, hospital systems, and academic centers, help accelerate adoption and strengthen evidence generation. Companies that proactively engage in clinician education and structured real-world data collection are able to translate clinical insights into clearer purchasing rationales. Finally, go-to-market effectiveness depends on aligning field teams with high-value clinical targets and ensuring that reimbursement and supply chain narratives are integrated into sales conversations to reduce adoption friction

Actionable recommendations for industry leaders to optimize product development, strengthen supply resilience, enhance payer engagement, and boost clinician uptake

Industry leaders should pursue a pragmatic set of strategic actions that balance near-term operational resilience with mid-term clinical and commercial positioning. First, strengthen supply chain resilience by diversifying sourcing, increasing logistics visibility, and negotiating contractual terms that offer price stability and prioritized allocations in the event of disruption. Second, align product development roadmaps with clear clinical pain points; prioritize improvements that shorten application time, reduce preparation complexity, and enhance compatibility with common operative workflows.

Third, invest in evidence generation that explicitly maps product attributes to clinically meaningful outcomes and economic endpoints relevant to payers and hospital procurement committees. Fourth, build differentiated commercialization models that combine product supply with clinician training, outcome monitoring, and procedural toolkits to minimize adoption friction and demonstrate value. Fifth, proactively engage with payers and health system procurement teams to articulate value propositions in terms they prioritize-efficiency gains, complication reduction, or throughput improvements.

Finally, create buyer-focused value propositions for different end user settings, recognizing that ambulatory surgical centers, clinics, and hospitals have distinct priorities. By combining operational safeguards with evidence-based commercial strategies, companies and health systems can accelerate adoption while protecting margins and clinical continuity

Research methodology covering data collection approaches, integration of primary and secondary sources, validation protocols and analytics for rigor

The research integrates multiple methodological strands to ensure robustness and relevance. Primary engagement included structured interviews with practicing surgeons, OR nursing leads, procurement officers, and supply chain managers to capture first-hand perspectives on product handling, clinical trade-offs, and purchasing constraints. These qualitative inputs were cross-referenced with a systematic review of peer-reviewed clinical literature and guideline statements to validate clinical claims and to identify procedure-specific evidence gaps.

On the commercial side, the study analyzed procurement policy trends, public tender templates, and hospital purchasing workflows to understand contract dynamics and decision levers. Validation protocols included triangulation across stakeholder interviews, literature findings, and observed procurement patterns in representative hospitals. Analytical techniques employed included scenario-based supply chain stress testing, qualitative thematic synthesis of clinician interviews, and structured gap analysis to identify unmet needs in product features or evidence generation.

Throughout, care was taken to ensure transparency in source attribution, to document potential biases, and to include sensitivity checks where stakeholder views diverged. The methodology balances depth of clinician insight with breadth of regulatory and procurement context to produce conclusions that are both empirically grounded and operationally actionable

Concise conclusion synthesizing strategic implications and actionable next steps for stakeholders pursuing clinical impact and commercial value

This analysis synthesizes clinical, commercial, regulatory, and supply chain perspectives to present a cohesive set of implications for stakeholders. The evidence indicates that clinical adoption will increasingly favor products that align with procedural efficiency and demonstrable outcome improvements, while procurement decisions will be shaped by both cost considerations and supplier reliability. The confluence of evolving delivery technologies and payer scrutiny calls for integrated strategies that pair product innovation with robust evidence and practical support for clinicians.

Operationally, the priority is to ensure supply continuity and predictable pricing in a changing trade and tariff environment. Institution-level risk management, including inventory policy adjustments and multi-sourced supply agreements, will be essential to mitigate potential disruptions. On the commercial front, firms that can present clear, quantifiable value propositions to payers and hospital procurement teams will have a competitive advantage in capturing long-term institutional contracts.

In conclusion, decision-makers should view fibrin sealant strategy through a multifaceted lens that incorporates product differentiation, evidence generation, supply chain robustness, and region-specific commercialization. By integrating these dimensions into cohesive action plans, stakeholders can translate the research insights into meaningful clinical and economic outcomes

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Fibrin Sealant Market, by Product Type

  • 8.1. Liquid
  • 8.2. Patch
  • 8.3. Spray

9. Fibrin Sealant Market, by Formulation Type

  • 9.1. Pre Mixed
  • 9.2. Two Component Kits

10. Fibrin Sealant Market, by Technology

  • 10.1. Manual Application
  • 10.2. Spray Application

11. Fibrin Sealant Market, by Application

  • 11.1. Cardiovascular
    • 11.1.1. Bypass
    • 11.1.2. Valve Repair
  • 11.2. Dental
  • 11.3. General Surgery
    • 11.3.1. Abdominal
    • 11.3.2. Thoracic
  • 11.4. Neurosurgery
  • 11.5. Orthopedic
    • 11.5.1. Joint Reconstruction
    • 11.5.2. Trauma Fixation
  • 11.6. Wound Care

12. Fibrin Sealant Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
  • 12.3. Hospitals

13. Fibrin Sealant Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Fibrin Sealant Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Fibrin Sealant Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Fibrin Sealant Market

17. China Fibrin Sealant Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. B. Braun Melsungen AG
  • 18.6. Baxter International Inc.
  • 18.7. Bayer AG
  • 18.8. CryoLife, Inc.
  • 18.9. CSL Behring GmbH
  • 18.10. Ethicon Inc.
  • 18.11. FzioMed Inc.
  • 18.12. Haemacure Corporation
  • 18.13. Hemarus Therapeutics (India) Pvt. Ltd.
  • 18.14. Hemostasis LLC
  • 18.15. Hualan Biological Engineering Inc.
  • 18.16. Hunan Kelun-Biotech Co., Ltd.
  • 18.17. Integra LifeSciences Corporation
  • 18.18. LFB Group
  • 18.19. Mallinckrodt Pharmaceuticals Holdings Inc.
  • 18.20. Omrix Biopharmaceuticals Ltd.
  • 18.21. Omrix Biopharmaceuticals, Inc.
  • 18.22. Sanofi S.A.
  • 18.23. Shanghai Haoyuan Biological Manufacturing Co., Ltd.
  • 18.24. Shanghai Haoyuan Biological Manufacturing Co., Ltd.
  • 18.25. Shanghai Hualan Biological Engineering Inc.
  • 18.26. Shanghai RAAS Blood Products Co., Ltd.
  • 18.27. Shanghai RAAS Blood Products Co., Ltd.
  • 18.28. Tissuemed Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FIBRIN SEALANT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FIBRIN SEALANT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FIBRIN SEALANT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FIBRIN SEALANT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FIBRIN SEALANT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FIBRIN SEALANT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES FIBRIN SEALANT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA FIBRIN SEALANT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FIBRIN SEALANT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FIBRIN SEALANT MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FIBRIN SEALANT MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FIBRIN SEALANT MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FIBRIN SEALANT MARKET SIZE, BY PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FIBRIN SEALANT MARKET SIZE, BY PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FIBRIN SEALANT MARKET SIZE, BY PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FIBRIN SEALANT MARKET SIZE, BY SPRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FIBRIN SEALANT MARKET SIZE, BY SPRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FIBRIN SEALANT MARKET SIZE, BY SPRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FIBRIN SEALANT MARKET SIZE, BY PRE MIXED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FIBRIN SEALANT MARKET SIZE, BY PRE MIXED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FIBRIN SEALANT MARKET SIZE, BY PRE MIXED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FIBRIN SEALANT MARKET SIZE, BY TWO COMPONENT KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FIBRIN SEALANT MARKET SIZE, BY TWO COMPONENT KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FIBRIN SEALANT MARKET SIZE, BY TWO COMPONENT KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FIBRIN SEALANT MARKET SIZE, BY MANUAL APPLICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FIBRIN SEALANT MARKET SIZE, BY MANUAL APPLICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FIBRIN SEALANT MARKET SIZE, BY MANUAL APPLICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FIBRIN SEALANT MARKET SIZE, BY SPRAY APPLICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FIBRIN SEALANT MARKET SIZE, BY SPRAY APPLICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FIBRIN SEALANT MARKET SIZE, BY SPRAY APPLICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FIBRIN SEALANT MARKET SIZE, BY BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FIBRIN SEALANT MARKET SIZE, BY BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FIBRIN SEALANT MARKET SIZE, BY BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FIBRIN SEALANT MARKET SIZE, BY VALVE REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FIBRIN SEALANT MARKET SIZE, BY VALVE REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FIBRIN SEALANT MARKET SIZE, BY VALVE REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FIBRIN SEALANT MARKET SIZE, BY DENTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FIBRIN SEALANT MARKET SIZE, BY DENTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FIBRIN SEALANT MARKET SIZE, BY DENTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FIBRIN SEALANT MARKET SIZE, BY ABDOMINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FIBRIN SEALANT MARKET SIZE, BY ABDOMINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FIBRIN SEALANT MARKET SIZE, BY ABDOMINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FIBRIN SEALANT MARKET SIZE, BY THORACIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FIBRIN SEALANT MARKET SIZE, BY THORACIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FIBRIN SEALANT MARKET SIZE, BY THORACIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FIBRIN SEALANT MARKET SIZE, BY NEUROSURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FIBRIN SEALANT MARKET SIZE, BY NEUROSURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FIBRIN SEALANT MARKET SIZE, BY NEUROSURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FIBRIN SEALANT MARKET SIZE, BY JOINT RECONSTRUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FIBRIN SEALANT MARKET SIZE, BY JOINT RECONSTRUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FIBRIN SEALANT MARKET SIZE, BY JOINT RECONSTRUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FIBRIN SEALANT MARKET SIZE, BY TRAUMA FIXATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FIBRIN SEALANT MARKET SIZE, BY TRAUMA FIXATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FIBRIN SEALANT MARKET SIZE, BY TRAUMA FIXATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FIBRIN SEALANT MARKET SIZE, BY WOUND CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FIBRIN SEALANT MARKET SIZE, BY WOUND CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL FIBRIN SEALANT MARKET SIZE, BY WOUND CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FIBRIN SEALANT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL FIBRIN SEALANT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FIBRIN SEALANT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FIBRIN SEALANT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FIBRIN SEALANT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL FIBRIN SEALANT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL FIBRIN SEALANT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL FIBRIN SEALANT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL FIBRIN SEALANT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL FIBRIN SEALANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS FIBRIN SEALANT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA FIBRIN SEALANT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL FIBRIN SEALANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GCC FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. GCC FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. GCC FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. GCC FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 165. GCC FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 167. GCC FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. G7 FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. G7 FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. G7 FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. G7 FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 192. G7 FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 194. G7 FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. NATO FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. NATO FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. NATO FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. NATO FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 201. NATO FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 203. NATO FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES FIBRIN SEALANT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA FIBRIN SEALANT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)